![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Mesa Biotech Garners FDA Clearance and CLIA Waiver for Flu Test
Mesa Biotech Garners FDA Clearance and CLIA Waiver for Flu Test
![ClearanceStamp_Blue.gif](https://www.fdanews.com/ext/resources/test/Device_Images6/ClearanceStamp_Blue.gif?t=1576043968&width=430)
February 8, 2018
Mesa Biotech obtained FDA 510(k) clearance and a Clinical Laboratory Improvements Amendments waiver for its Accula Flu A/Flu B test.
The disposable point-of-care test cassette is the first one to receive FDA clearance for use on the company’s polymerase chain reaction Accula testing platform, featuring a portable dock. It can provide test results in about 30 minutes using samples from nasal swabs.
The San Diego-based molecular diagnostic company received a CE Mark for the assay-specific product just last month.
Upcoming Events
-
21Oct